About

Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly differentiated ADC platforms and expertise to rapidly design and test novel ADCs and identify those with optimal efficacy, safety and tolerability. Using this strategy, we are building a robust pipeline of ADC candidates with the potential to make a life-changing difference for people living with cancer. Our lead candidate, upifitamab rilsodotin (UpRi), is a first-in-class Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registration study, in patients with platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase 1 umbrella study, combining UpRi with other ovarian cancer therapies. XMT-1592, our second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).

Our experienced management team shares a strong commitment to scientific excellence and patient care, while also cultivating a highly collaborative and welcoming workplace. At Mersana, we have a passion for advancing therapies that make a significant impact in the lives of people living with cancer.

Mission

Mersana’s mission is to discover and develop life-changing antibody-drug conjugates for patients fighting cancer.

Vision

To create a world where all patients triumph over cancer.